U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07774975) titled 'Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa' on Aug. 15.
Brief Summary: Retinitis pigmentosa (RP) is a rare inherited retinal degenerative disease that causes progressive visual field loss and vision impairment, often leading to blindness. Currently, there are limited treatment options capable of slowing disease progression for the majority of patients with RP. Preclinical studies have suggested that retinal inflammation, particularly the activity of inflammatory monocytes and macrophages, may contribute to photoreceptor degeneration. ULREA-PVS-NP is a novel intravenous formulation consisting ...